Also known as Tibsovo, ivosidenib is a small molecule IDH1 inhibitor that was approved by the Food Drug Administration (FDA) in 2021 for the treatment of IDH1 mutated locally advanced or metastatic CCA. The gene discussed is IDH1; the disease is cholangiocarcinoma.